Jon Faiz Kayyem - 05 Jun 2024 Form 4 Insider Report for Inhibrx Biosciences, Inc. (INBX)

Role: Director
Signature: /s/ Kelly Deck, as attorney-in-fact to Jon Faiz Kayyem
Issuer symbol: INBX
Transactions as of: 05 Jun 2024
Transactions value $: $997,024
Form type: 4
Filing time: 07 Jun 2024, 18:05:13 UTC
Previous filing: 04 Jun 2024
Next filing: 24 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INBX	Common Stock	Purchase	$849K	+49.3K	+4.51%	$17.23^*	1.14M	05 Jun 2024	By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust	F1
transaction	INBX	Common Stock	Purchase	$148K	+8.27K	+0.72%	$17.89^*	1.15M	05 Jun 2024	By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares were purchased in multiple transactions at prices ranging from $16.81 to $17.805, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F2	The shares were purchased in multiple transactions at prices ranging from $17.81 to $18.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

Content

The shares were purchased in multiple transactions at prices ranging from $16.81 to $17.805, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

The shares were purchased in multiple transactions at prices ranging from $17.81 to $18.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.